ArticleEuropean journal of neurology2025
Longitudinal Brain Atrophy Patterns in Early MOG-Antibody Associated Disease and Relapsing Multiple Sclerosis.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal Brain Atrophy Patterns in Early MOG-Antibody Associated Disease and Relapsing Multiple Sclerosis.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMyelin oligodendrocyte glycoprotein antibody-associated disease can manifest as a relapsing or monophasic condition. Although several MRI studies have shown evident gray and white matter atrophy compared to healthy controls, little is known about regional brain volume dynamics in myelin oligodendrocyte glycoprotein antibody-associated disease over time.
methodsIn this study, we performed an explorative voxel-based morphometry to detect brain volumetric differences between myelin oligodendrocyte glycoprotein antibody-associated disease (N = 27), relapsing multiple sclerosis (N = 40)-both in early disease stages-and healthy controls (N = 45). Furthermore, we investigated the longitudinal brain volume changes over a 2-year follow-up period in myelin oligodendrocyte glycoprotein antibody-associated disease (N = 15) and relapsing multiple sclerosis (N = 40).
resultsWe identified distinct patterns of regional brain volume loss in the patient subgroups compared to healthy controls. In multiple sclerosis patients, bilateral thalamic atrophy was observed, whereas patients with myelin oligodendrocyte glycoprotein antibody-associated disease showed atrophy of the bilateral fornix and stria terminalis. Our results confirmed longitudinal volume loss in thalamic and infratentorial regions in the relapsing multiple sclerosis group, which was partly related to clinical relapses during the 2-year follow-up period. In contrast, no longitudinal gray or white matter changes were found in the myelin oligodendrocyte glycoprotein antibody-associated disease group.
conclusionsTo our knowledge, this is the first MRI study demonstrating no evidence of regional brain volume loss over time in patients with myelin oligodendrocyte glycoprotein antibody-associated disease using voxel-based morphometry, suggesting a different-probably not progressive-pathophysiological background compared to relapsing multiple sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.